GE HealthCare Technologies Inc. (GEHC)
| Market Cap | 28.88B -19.6% |
| Revenue (ttm) | 21.27B +6.5% |
| Net Income | 1.99B -11.4% |
| EPS | 4.34 -11.1% |
| Shares Out | 451.69M |
| PE Ratio | 14.73 |
| Forward PE | 12.36 |
| Dividend | $0.14 (0.22%) |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | 3,205,136 |
| Open | 64.96 |
| Previous Close | 64.24 |
| Day's Range | 63.22 - 65.40 |
| 52-Week Range | 58.75 - 89.77 |
| Beta | 0.82 |
| Analysts | Buy |
| Price Target | 82.50 (+29.05%) |
| Earnings Date | Oct 28, 2026 |
About GEHC
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, an... [Read more]
Financial Performance
In 2025, GEHC's revenue was $20.63 billion, an increase of 4.84% compared to the previous year's $19.67 billion. Earnings were $2.08 billion, an increase of 4.57%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for GEHC stock is "Buy." The 12-month stock price target is $82.5, which is an increase of 29.05% from the latest price.
News
GE HealthCare Technologies Transcript: Wells Fargo 21st Annual Healthcare Conference
Q2 saw 11% order growth and a strong backlog, with new products and robust demand supporting future quarters. Margins are set to improve in the second half, while China stabilizes and PDX outperforms expectations. Strategic review updates and new product contributions are expected in 2027.
GE HealthCare announces StarGuide GX is 510k pending with U.S. FDA
GE HealthCare (GEHC) announced that StarGuide GX, its new digital 4D CZT SPECT/CT technology, is 510(k) pending with the U.S. Food and Drug Administration, FDA. This milestone is a step…
GE HealthCare aims to advance a new era in theranostics with StarGuide™ GX 4D SPECT/CT, now 510(k) pending with the U.S. FDA
CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced that StarGuide GX,i its new digital 4D CZT SPECT/CT technology, is 510(k) pending with the U.S. Food and Drug Administration (FDA). Building on ...
GE HealthCare receives CE Mark for Photonova Spectra
GE HealthCare (GEHC) recently achieved CE Mark for Photonova Spectra, an advanced photon-counting computed tomography system with the company’s proprietary Deep Silicon detector technology. The compan...
GE HealthCare's Photonova™ Spectra gains CE Mark, expanding international access
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) recently achieved CE Mark for Photonova Spectra,i an advanced photon-counting computed tomography (PCCT) system with the company's proprietary De...
GE HealthCare unveils the next generation of the Vivid cardiovascular ultrasound portfolio, enabling advanced cardiac imaging across care settings
CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced three additions to its Vivid™ cardiovascular ultrasound portfolio – Vivid™ Explorer, Vivid™ Advanced and Vivid™ Focus.
GE HealthCare management to present at upcoming investor conference
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conference: Wells Fargo 21st Annual Health Conf...
GE HealthCare appoints William Grogan as CFO, replacing Jay Saccaro
GE HealthCare said on Tuesday it had appointed William Grogan chief financial officer, effective September 14, succeeding Jay Saccaro after he stepped down last month.
GE HealthCare appoints Grogan as Chief Financial Officer
GE HealthCare (GEHC) announced the appointment of William Grogan as Chief Financial Officer, effective September 14, 2026. Grogan succeeds Jay Saccaro, who, as previously announced, stepped down for a...
GE HealthCare appoints William Grogan as Chief Financial Officer
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, today announced the appointment of William (Bill) Grogan as Chief Financial Officer, effective Septem...
GE HealthCare expands LOGIQ e ultrasound platform with new LOGIQ e family
GE HealthCare (GEHC) announced the introduction of the LOGIQ e family, featuring LOGIQ e Xi and LOGIQ e Si, two compact laptop ultrasound systems designed to help clinicians deliver fast…
GE HealthCare expands the LOGIQ e ultrasound platform with new LOGIQ e family
CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced the introduction of the LOGIQ™ e family, featuring LOGIQ™ e Xi and LOGIQ™ e Si, two compact laptop ultrasound systems designed to help clinician...
GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime
GE HealthCare (GEHC) announced the launch of Invenia ABUS Prime and ABUS StreamVue, a redesigned enterprise viewer that recently received U.S. Food and Drug Administration, FDA, 510(k) clearance and C...
GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue
CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced the launch of Invenia™ ABUS (Automated Breast Ultrasound) Prime and ABUS StreamVue™, a redesigned enterprise viewer that recently received U.S. ...
GE HealthCare price target raised to $73 from $67 at UBS
UBS raised the firm’s price target on GE HealthCare (GEHC) to $73 from $67 and keeps a Neutral rating on the shares.
GE HealthCare price target raised to $70 from $65 at JPMorgan
JPMorgan raised the firm’s price target on GE HealthCare (GEHC) to $70 from $65 and keeps a Neutral rating on the shares.
GE HealthCare price target raised to $84 from $80 at Evercore ISI
Evercore ISI raised the firm’s price target on GE HealthCare (GEHC) to $84 from $80 and keeps an Outperform rating on the shares.
GE HealthCare price target raised to $75 from $69 at Citi
Citi raised the firm’s price target on GE HealthCare (GEHC) to $75 from $69 and keeps a Neutral rating on the shares. The firm views the company’s Q2 report as…
GE HealthCare price target raised to $79 from $75 at BTIG
BTIG raised the firm’s price target on GE HealthCare (GEHC) to $79 from $75 and keeps a Buy rating on the shares following quarterly results. The firm sees Q2 results…
GE HealthCare Technologies Earnings Call Transcript: Q2 2026
Orders grew 11% year-over-year with record backlog, and revenue rose 3.5% organically, driven by strong performance in Advanced Imaging and Pharmaceutical Diagnostics. PCS faced operational challenges but is expected to recover in the second half. Full-year guidance is maintained.
GE HealthCare Technologies Slides: Q2 2026
GE HealthCare Technologies has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
GE HealthCare Technologies Earnings release: Q2 2026
GE HealthCare Technologies released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
GE HealthCare Technologies Quarterly report: Q2 2026
GE HealthCare Technologies has published its Q2 2026 quarterly earnings report on July 29, 2026.
GE HealthCare Stock Soars After Earnings. Here's What Drove the Profit Gains.
GE HealthCare reports earnings per share of $1.13 from sales of $5.3 billion. Wall Street was looking for $1.04 a share and $5.3 billion, respectively.
GE HealthCare beats quarterly profit estimates on strong imaging demand, tariff refunds
GE HealthCare on Wednesday beat Wall Street estimates for second-quarter profit, helped by strong demand for its diagnostic and imaging devices and refunds of tariffs imposed under U.S. President Don...